Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors Thomas Yau, Yoon-Koo Kang, Tae-You Kim, Anthony B. El-Khoueiry, Armando Santoro, Bruno Sangro, Ignacio Melero, Masatoshi Kudo, Ming-Mo Hou, Ana Matilla, Francesco Tovoli, Jennifer J. Knox, Aiwu Ruth He, Bassel F. El-Rayes, Mirelis Acosta-Rivera, Jaclyn Neely, Yun Shen, Carlos Baccan, Christine Marie Dela Cruz, Chiun Hsu
Title Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
Journal J Clin Oncol
Vol
Issue
Date
URL https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.4012
Abstract Text J Clin Oncol 37, no. 15_suppl (May 20, 2019) 4012-4012

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown hepatocellular carcinoma not applicable Ipilimumab + Nivolumab FDA approved Actionable In a Phase I (CheckMate 040) trial that supported FDA approval, combination of Opdivo (nivolumab) and Yervoy (ipilimumab) was well tolerated, resulted in an objective response rate of 32% (16/50, 4 complete response, 12 partial response) with a median duration of response of 17 months in patients with hepatocellular carcinoma previously treated with Nexavar (sorafenib) (J Clin Oncol 37, no. 15_suppl (May 20, 2019) 4012-4012; NCT01658878). detail... detail... detail...